Clinical Trials Logo

IgG Deficiency clinical trials

View clinical trials related to IgG Deficiency.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01847781 Completed - IgG Deficiency Clinical Trials

PNEUMOCELL - Conjugated Pneumococcal Vaccination in Patients With Immunoglobulin G-deficiency

PNEUMOCELL
Start date: May 2013
Phase: Phase 2
Study type: Interventional

The aim is to study the immune response to conjugated pneumococcal vaccination (Prevenar13) in Immunoglobulin G-deficient patients and healthy controls. Our hypothesis is that the antibody response will be impaired in patients as compared with controls. In contrast, we postulate that the cellular immune response will be intact.

NCT ID: NCT00522821 Completed - Infections Clinical Trials

Treatment of Deficient Subclass or Anti-polysaccharide Antibody Response

Subklasse
Start date: November 2007
Phase: Phase 4
Study type: Interventional

There is no consensus on the treatment of patients with recurrent infections and isolated immunoglobulin G (IgG)-subclass deficiency and/or selective antipolysaccharide antibody deficiency. Therefore, the Dutch Inter University Working Party will start a study in which the treatment with antibiotics is compared with intravenous immunoglobulin therapy with respect to clinical outcome measures in both children and adults with this disorder.

NCT ID: NCT00417573 Completed - Infections Clinical Trials

Efficacy of IgIv in Patients With IgG Subclass Deficiency and Recurrent Infections

Start date: December 2004
Phase: Phase 2
Study type: Interventional

- This is the first study, that we are aware of, that will evaluate the efficacy of IgIV in patients with IgG subclass deficiency. - Will provide data for further collaboration in extending study to involve other immunological centers in the United States to study patients with similar disease.

NCT ID: NCT00322556 Completed - Clinical trials for Common Variable Immunodeficiency

Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)

Start date: November 2005
Phase: Phase 3
Study type: Interventional

The objectives of this trial are the assessment of safety and efficacy of IgPro10 in patients with PID, and the assessment of tolerability of high infusion rates. To demonstrate safety, the number of infusions temporally associated with AEs, the rate, severity and relationship of all AEs and the vital sign changes during each infusion will be evaluated.

NCT ID: NCT00168025 Completed - Clinical trials for Common Variable Immunodeficiency

Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)

Start date: September 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate the effect of IgPro10 on the prevention of serious bacterial infections in patients with primary immunodeficiency. As secondary endpoints the rate of overall infections, the tolerability and safety of IgPro10 are studied. A part of the patients are participating in a pharmacokinetic substudy.

NCT ID: NCT00168012 Completed - Clinical trials for Common Variable Immunodeficiency

Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)

Start date: September 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate the effect of IVIG-F10 on the prevention of serious bacterial infections in patients with primary immunodeficiency. As secondary endpoints the rate of overall infections, the tolerability and safety of IVIG-F10 are studied.